Eric Green

Company: Trace Neurosciences

Job title: Co-Founder & Chief Executive Officer

Seminars:

UNC13A Restoration as a Novel Genetically Validated Approach to ALS 10:30 am

Exploring Genetics in ALS: across rare Familial Forms and sporadic population Target validation, mechanisms and biology of UNC13A Discovery and development of medicines for UNC13ARead more

day: Conference Day Two Workshop B

Panel Discussion: Strategic Funding & Resource Allocation in ALS Research: Overcoming Barriers to Clinical Development 8:30 am

ALS trials are highly resource-intensive, with significant financial and logistical demands, creating a major barrier for therapies entering development Strategies like synthetic control arms, remote visits, and digital biomarkers can cut costs and reduce patient burden, though validation of these technologies remains a challenge Investors prioritize ALS programs with unique therapeutic approaches, including gene therapy…Read more

day: Conference Day One